| ADR Ontology |
| ADR Term |
Pseudolymphoma |
| ADR ID |
BADD_A03606 |
| ADR Hierarchy |
|
| Description |
A group of disorders having a benign course but exhibiting clinical and histological features suggestive of malignant lymphoma. Pseudolymphoma is characterized by a benign infiltration of lymphoid cells or histiocytes which microscopically resembles a malignant lymphoma. (From Dorland, 28th ed & Stedman, 26th ed) [MeSH] |
| MedDRA Code |
10037127 |
| MeSH ID |
D019310
|
|
ADR Severity Grade (FAERS)
|
|
|
ADR Severity Grade (CTCAE)
|
Not Available
|
| Synonym |
| Benign lymphoma | Hodgkin's-like | Hodgkins-like | Lymphoma benign | Lymphoma like reaction | Lymphoma-like disorder | Lymphoma-like reaction | Lymphomoid | Lymphosarcomoid | Pseudo lymphoma | Pseudolymphoma | Reaction lymphoma-like | Lymphocytoma cutis | Pseudolymphomas | Lymphoid Hyperplasia, Reactive | Lymphocytoma | Lymphocytomas | Hyperplasia, Reactive Lymphoid | Hyperplasias, Reactive Lymphoid | Lymphoid Hyperplasias, Reactive | Reactive Lymphoid Hyperplasia | Reactive Lymphoid Hyperplasias |
|
|
| ADR Related Proteins |
| Protein Name |
UniProt AC |
TTD Target ID |
| Not Available | Not Available | Not Available |
|
| Drugs Leading to the ADR |
| Drug ID | Drug Name | ADR Frequency (FAERS) | ADR Severity Grade (FAERS) | | BADD_D02344 | Vemurafenib | 0.000650% | |
| The 2th Page First
Pre
2
Total 2 Pages
|
|
